Centers for Medicare & Medicaid Services (CMS) announced they will not move forward with a proposed change to the Part D Payment Modernization Model that could have resulted in seniors losing access to critical drugs—a win for the most vulnerable patients.
Catch up: The outgoing Trump administration announced a new policy that would have allowed insurance plans to cover fewer drugs in their formularies in six protected classes (antidepressants, antipsychotics, anticonvulsants, immunosuppressants for treatment of transplant rejection, antiretrovirals for treatment of HIV, and antineoplastics).
Medicare Part D sponsors have been required to cover ALL FDA-approved drugs in these six classes—but the proposed change could have resulted in “seniors losing access to treatments they rely on,” explained BIO President and CEO Dr. Michelle McMurry-Heath.
Yesterday, CMS announced they would NOT move forward with the proposed change—here’s the full update on the CMS website.
This is a win for patients—made possible in part by the patient groups who worked around the clock to engage CMS on this important issue.
More Health Care News:
CNN: First children vaccinated in Moderna's Phase 2/3 pediatric COVID-19 vaccine trial
“The clinical trial, called the KidCOVE study, will enroll approximately 6,750 children in the US and Canada between the ages of 6 months and 11 years old.”
Fast Company: Pfizer’s CEO reflects on a year of discovery and what he thinks critics get wrong about vaccine pricing
“We were highly motivated to be able to do a good thing for humanity and both the collaboration and the competitive spirit was what helped us to create what we created,” he said.
